Session » Systemic Sclerosis & Related Disorders – Clinical Poster III

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2600

‘If You Don’t Use It, You Lose It’: Rehabilitation of Finger Dexterity and Ability to Perform Activities of Daily Living in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2609

Anti-angiogenic VEGF-A165b Is Associated with Systemic Sclerosis Peripheral Vasculopathy

9:00AM-11:00AM: Abstract Number: 2618

Anti-RNPC-3 Antibodies Are Associated with Nuclear Speckled Immunofluorescence Pattern and Enriched in Triple Negative Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2614

Association of Body Composition in Scleroderma Patients with Disease Activity, Serum Levels of Inflammatory Cytokines and Parameters of Nutrition and Lipid Metabolism

9:00AM-11:00AM: Abstract Number: 2594

Associations Between Antibodies to the Angiotensin II Type 1 Receptor and Endothelian-1 Type a Receptor and the Incidence of Vascular Complications in Early Diffuse Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2595

Asymptomatic Scleroderma Antibody Positivity and Progression to Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2599

Body Composition and Nailfold Videocapillaroscopy Patterns in a Cohort of Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2602

Changes in Fecal Microbiota Composition After Fecal Microbiota Transplantation in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2586

Clinical Characteristics and Survival in Systemic Sclerosis-mixed Connective Tissue Disease and Systemic Sclerosis-overlap Syndrome

9:00AM-11:00AM: Abstract Number: 2590

Computer Vision Applied to Dual Energy Computed Tomography Images for Precise Calcinosis Cutis Quantification in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2603

Course of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in the EUSTAR Database

9:00AM-11:00AM: Abstract Number: 2615

Cumulative Incidence, Survival and Predictors of Pulmonary Arterial Hypertension in Disease Subsets of Systemic Sclerosis: PAH Is Not Increased in Limited vs Diffuse Patients by Adjusted Competing Risk Analysis

9:00AM-11:00AM: Abstract Number: 2593

Cyclophosphamide for the Treatment of Skin Fibrosis in Systemic Sclerosis: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2598

Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon

9:00AM-11:00AM: Abstract Number: 2606

Evolution of Systemic Sclerosis-Related Interstitial Lung Disease After Autologous Hematopoietic Stem Cell Transplantation

9:00AM-11:00AM: Abstract Number: 2616

Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort

9:00AM-11:00AM: Abstract Number: 2591

Hospitalization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1980-2016)

9:00AM-11:00AM: Abstract Number: 2613

Hsp90 as a Potential Biomarker of Lung and Skin Involvement in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2592

Longitudinal Changes in Health-related Quality of Life in Systemic Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplant Compared to Standard of Care

9:00AM-11:00AM: Abstract Number: 2605

Men and Black Persons Die at Younger Ages from Systemic Sclerosis: A Nationwide Population-based Study

9:00AM-11:00AM: Abstract Number: 2611

Mesenchymal Stem Cells in Scleroderma: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2612

Minocycline for Refractory Calcinosis in Systemic Sclerosis: A Single-Centre Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 2588

Myositis-specific and -associated Antibodies in Systemic Sclerosis: Prevalence and Clinical Associations

9:00AM-11:00AM: Abstract Number: 2604

Pain Chronification and the Important Role of Non-disease Specific Symptoms in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2597

Prevalence and Clinical Associations of Degos Lesions in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2587

Prognostic Role of Measurement of Renal Resistive Index in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2610

Relationship Between Parenchymal and Vascular Features in Systemic Sclerosis-Interstitial Lung Disease: Results from Quantitative Analysis of Chest Computed Tomography

9:00AM-11:00AM: Abstract Number: 2617

Responsiveness to Change of the Modified Rodnan Skin Score in a Phase I/II Double-Blind Randomized Placebo-Controlled Trial

9:00AM-11:00AM: Abstract Number: 2589

Searching the Calcinosis Signature: A Case Control Study Analyzing Limited Systemic Sclerosis Female Patients with and Without Calcinosis, Paired by Disease Duration, Age and Body Mass Index

9:00AM-11:00AM: Abstract Number: 2608

Subsets in Systemic Sclerosis-ILD: Working Towards Consensus-Based Definitions

9:00AM-11:00AM: Abstract Number: 2596

The Contribution of Left Heart Disease in Patients with Systemic Sclerosis-associated Pulmonary Hypertension Having Normal Pulmonary Artery Wedge Pressure

9:00AM-11:00AM: Abstract Number: 2601

Trabecular Bone Score and Malnutrition in a Cohort of Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2607

Ultrasound Detection of Calcinosis and Correlation with Ulnar Artery Occlusion in Patients with Systemic Sclerosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].